Hemangiopericytomas and malignant solitary fibrous tumors (HPC/SFT) are rare, closely related sarcomas with unpredictable behavior that respond infrequently to chemotherapy. Because of the vascular compnent, Avastin may be active in this disease. Several reports and small studies have explored it in variosu combiantions, inluding with temazolamide. A recent retrosepctive review of 14 patients*Park et al) concluded: “Combination therapy with temozolomide and bevacizumab is a generally well-tolerated and clinically beneficial regimen for HPC/SFT patients. Additional investigation in a controlled, prospective trial is warranted.”
Min S Park, Shreyaskumar R Patel, Joseph A Ludwig, Jonathan C Trent, Charles A Conrad, … Alexander J Lazar, Wei-Lien Wang, Piyaporn Boonsirikamchai, Haesun Choi, Xuemei Wang, Robert S Benjamin, Dejka M Araujo Miscellaneous Papers In your library Save reference to library
ShareActivity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.
Cancer (2011) DOII: 10.1002/cncr.26098
Julien Domont, Christophe Massard, Nathalie Lassau, Jean-Pierre Armand, Axel Le Cesne and Jean-Charles Soria
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour Investigational New Drugs Volume 28, Number 2, 199-202,